|
Published by: Decision Resources
Published: Dec. 5, 2008 - 26 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Reactive Arthritis
- Disease Description and Etiology
- Clinical Manifestations
- Joint Symptoms
- Eye Symptoms
- Skin Symptoms
- Epidemiology
- Overview
- Disease Defi nition
- Methods
- Current Therapies for Reactive Arthritis
- NSAIDs
- Conventional Disease-Modifying Antirheumatic Drugs
- The Use of Biologics in Reactive Arthritis
- Current Role of Biologic Therapy
- Emerging Biologic Therapies
- Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe’s Golimumab
- Biogen Idec/Genentech/Roche’s Ocrelizumab
- Interleukin-Based Therapies
- Outlook for the Reactive Arthritis Market
- Bibliography
- Tables
- 1. Agents Used in the Treatment of Reactive Arthritis
- 2. Approved TNF-á Inhibitors, 2008
- 3. Emerging Biologic Agents, 2008
- Figures:
- 1. Specialist’s Estimates of Reactive Arthritis Symptom Frequency
- 2. Prevalent Cases of Reactive Arthritis in the United States, 2007-2017
- 3. Survey Question: Please indicate your fi rst-line therapy choice for reactive arthritis
- 4. Survey Question: Please indicate your second-line therapy choice for reactive arthritis
- 5. Survey Question: Please indicate your third-line therapy choice for reactive arthritis
- 6. Survey Question: How many of your patients will require new or additional therapy within the following time frames?
- 7. Survey Question: What percentage of your reactive arthritis patients receive the following biologic therapies?
- 8. Survey Question: Would you prescribe golimumab to your reactive arthritis patients?
- 9. Survey Question: Would you prescribe tocilizumab to your reactive arthritis patients?
- 10. Survey Question: What agents are most likely to be replaced by golimumab?
- 11. Survey Question: What agents are most likely to be replaced by tocilizumab?
AbstractIntroduction
Reactive arthritis (ReA), a seronegative spondyloarthropathy that is believed to be partially autoimmune and
triggered by the presence of a bacterial infection, is rare. For that reason, along with the availability of generic
agents and the relatively benign nature of the disease, the market for reactive arthritis therapies is limited.
Nonetheless, the treatment of chronic and refractory reactive arthritis remains a target for drug development.
How promising a target? To answer that question, Decision Resources surveyed specialists to uncover their
treatment choices for reactive arthritis and to determine whether any emerging therapy will cause a signifi cant
change in the market.
Get the Answers You Need to Shape Your Strategy
- Reactive arthritis is an inflammatory disease triggered by a bacterial infection, usually gastrointestinal or
urogenital in origin. What are the symptoms of reactive arthritis? How is the disease diagnosed? What
are the drugs commonly used to treat reactive arthritis?
- Reactive arthritis is a rare disease that occasionally goes into spontaneous remission. How many individuals
in the United States are diagnosed with reactive arthritis? How will the diagnosed population grow
over the next ten years?
- Reactive arthritis mainly affects the joints, with chronic disease sometimes becoming debilitating. What
are specialists’ choices for fi rst-line therapies to treat reactive arthritis? Are there any agents in
development for ReA? What role will biologic therapies play in the treatment of ReA?
Scope
- Overview of reactive arthritis: disease defi nition, pathogenesis, symptoms, diagnosis
- Epidemiology: Diagnosed U.S. cases of reactive arthritis, 2007-2012
- Current therapies: Surveyed specialists’ therapy choices, NSAIDs, DMARDs
- Use of biologics in the treatment of reactive arthritis: TNF-á inhibitors, emerging biologic
therapies
- Outlook for reactive arthritis market: 2007 sales, outlook for emerging therapies
- This report is part of the Autoimmune Disease Series: In 2007, sales of agents used to treat
autoimmune disorders exceeded $20 billion. Still, for many of the more than 80 identifi ed
autoimmune disorders, treatment options are limited. Targeting underserved autoimmune diseases
offers drug developers the opportunity to introduce their agents into the autoimmune market
while taking advantage of the minimal competition and an expedited regulatory process. The
Autoimmune Disease Series provides critical market information, including disease prevalence,
profi les of marketed and emerging agents, and insight into the prescribing choices of disease
specialists.
Get Full Details About This Report >>
|
